research Phase I Clinical Testing Antimalarial Drugs.
Mefloquine was generally safe at 500 mg weekly, but higher doses caused nausea and diarrhea.
Search
for
Sort by
Research
990-1000 / 1000+ resultsresearch IMMUNOTHERAPY OF CANCER: IMMUNE CHECKPOINT BLOCKERS, VACCINES AND ADOPTIVE T CELL THERAPIES
Enhancing immune response can improve cancer treatment effectiveness.
research Pulse cyclophospamide in severe lupus nephritis: Southern Indian experience.
IV cyclophosphamide effectively treated severe lupus nephritis in Indian patients.
research Teriflunomide in multiple sclerosis: an update
Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.
research Simultaneous Onset of Alopecia Areata and Idiopathic Thrombocytopenic Purpura: A Potential Association?
A young girl had both alopecia areata and immune thrombocytopenic purpura at the same time, suggesting a possible link between the two.
research Successful discontinuation of levothyroxine in a known case of hypothyroidism through personalised homoeopathic treatment: An evidence-based case report
A woman with hypothyroidism stopped taking levothyroxine after successful homeopathic treatment.
research Alopecia areata (AA)
About half of people with mild alopecia areata see hair regrowth in a year, but relapses are common.
research New Drugs: Eculizumab
Eculizumab helps reduce blood transfusions and stabilize hemoglobin but increases infection risk and is expensive.
research Alopecia Associated with Fluconazole Therapy
Taking fluconazole for fungal infections might cause hair loss after about 3 months.
research Imbalance of T‐helper 17 and regulatory T cells in patients with alopecia areata
People with alopecia areata have more Th17 cells and fewer Treg cells, which may be key to the condition's development.